Juliet E Wolford1, Erin Ferrigni1, Daniel Margul1, Thomas J Herzog2,3. 1. Division of Gynecologic Oncology, University of Cincinnati, Cincinnati, OH, USA. 2. Division of Gynecologic Oncology, University of Cincinnati, Cincinnati, OH, USA. thomas.herzog@uc.edu. 3. University of Cincinnati Cancer Center, University of Cincinnati Medical Center, Medical Sciences Bldg., Suite 2005H, ML0662, 231 Albert Sabin Way, Cincinnati, OH, 45267-0662, USA. thomas.herzog@uc.edu.
Abstract
PURPOSE OF REVIEW: The treatment of patients with advanced gynecologic malignancies remains challenging. Advancements in genomics have led to recognition and development of individualized therapeutic targets. This article reviews the current trends in precision medicine for treatment of gynecologic cancers. RECENT FINDINGS: With the identification of the molecular aberrations inherent to gynecologic malignancies, we have discovered targetable mutations. Specific to ovarian, endometrial and cervical cancers, potential therapeutic targets that have been identified and shown to have benefit include: hormonal therapies, anti-angiogenic agents, poly-ADP-ribose polymerase inhibitors (PARPi), and immunotherapy. The adoption of targeted therapeutics for the treatment of gynecologic cancers has been gradual, but we have started to see the rapid employment of novel targeted agents into clinical trial development, leading to new treatment approvals. However, there are challenges to the universal precision medicine implementation, and future studies need to identify, discover, and validate robust biomarkers with strong prognostic/predictive capabilities.
PURPOSE OF REVIEW: The treatment of patients with advanced gynecologic malignancies remains challenging. Advancements in genomics have led to recognition and development of individualized therapeutic targets. This article reviews the current trends in precision medicine for treatment of gynecologic cancers. RECENT FINDINGS: With the identification of the molecular aberrations inherent to gynecologic malignancies, we have discovered targetable mutations. Specific to ovarian, endometrial and cervical cancers, potential therapeutic targets that have been identified and shown to have benefit include: hormonal therapies, anti-angiogenic agents, poly-ADP-ribose polymerase inhibitors (PARPi), and immunotherapy. The adoption of targeted therapeutics for the treatment of gynecologic cancers has been gradual, but we have started to see the rapid employment of novel targeted agents into clinical trial development, leading to new treatment approvals. However, there are challenges to the universal precision medicine implementation, and future studies need to identify, discover, and validate robust biomarkers with strong prognostic/predictive capabilities.
Authors: Asad Umar; C Richard Boland; Jonathan P Terdiman; Sapna Syngal; Albert de la Chapelle; Josef Rüschoff; Richard Fishel; Noralane M Lindor; Lawrence J Burgart; Richard Hamelin; Stanley R Hamilton; Robert A Hiatt; Jeremy Jass; Annika Lindblom; Henry T Lynch; Païvi Peltomaki; Scott D Ramsey; Miguel A Rodriguez-Bigas; Hans F A Vasen; Ernest T Hawk; J Carl Barrett; Andrew N Freedman; Sudhir Srivastava Journal: J Natl Cancer Inst Date: 2004-02-18 Impact factor: 13.506
Authors: Ann-Marie Patch; Elizabeth L Christie; Dariush Etemadmoghadam; Dale W Garsed; Joshy George; Sian Fereday; Katia Nones; Prue Cowin; Kathryn Alsop; Peter J Bailey; Karin S Kassahn; Felicity Newell; Michael C J Quinn; Stephen Kazakoff; Kelly Quek; Charlotte Wilhelm-Benartzi; Ed Curry; Huei San Leong; Anne Hamilton; Linda Mileshkin; George Au-Yeung; Catherine Kennedy; Jillian Hung; Yoke-Eng Chiew; Paul Harnett; Michael Friedlander; Michael Quinn; Jan Pyman; Stephen Cordner; Patricia O'Brien; Jodie Leditschke; Greg Young; Kate Strachan; Paul Waring; Walid Azar; Chris Mitchell; Nadia Traficante; Joy Hendley; Heather Thorne; Mark Shackleton; David K Miller; Gisela Mir Arnau; Richard W Tothill; Timothy P Holloway; Timothy Semple; Ivon Harliwong; Craig Nourse; Ehsan Nourbakhsh; Suzanne Manning; Senel Idrisoglu; Timothy J C Bruxner; Angelika N Christ; Barsha Poudel; Oliver Holmes; Matthew Anderson; Conrad Leonard; Andrew Lonie; Nathan Hall; Scott Wood; Darrin F Taylor; Qinying Xu; J Lynn Fink; Nick Waddell; Ronny Drapkin; Euan Stronach; Hani Gabra; Robert Brown; Andrea Jewell; Shivashankar H Nagaraj; Emma Markham; Peter J Wilson; Jason Ellul; Orla McNally; Maria A Doyle; Ravikiran Vedururu; Collin Stewart; Ernst Lengyel; John V Pearson; Nicola Waddell; Anna deFazio; Sean M Grimmond; David D L Bowtell Journal: Nature Date: 2015-05-28 Impact factor: 49.962
Authors: Ahmed Ashour Ahmed; Dariush Etemadmoghadam; Jillian Temple; Andy G Lynch; Mohamed Riad; Raghwa Sharma; Colin Stewart; Sian Fereday; Carlos Caldas; Anna Defazio; David Bowtell; James D Brenton Journal: J Pathol Date: 2010-05 Impact factor: 7.996
Authors: Ingeborg Klymiuk; Ceren Bilgilier; Alexander Mahnert; Andreas Prokesch; Christoph Heininger; Ingeborg Brandl; Hanka Sahbegovic; Christian Singer; Thorsten Fuereder; Christoph Steininger Journal: Front Oncol Date: 2022-08-09 Impact factor: 5.738